SODIUM-GLUCOSE TRANSPORTER 2 (SGLT2)
Steglatro is a prescription drug approved by the Food and Drug Administration (FDA) to help improve blood glucose control in adults with type 2 diabetes. Steglatro is considered an adjunct treatment to diet and exercise. Steglatro is also referred to by its drug name, Ertugliflozin.
Steglatro is a sodium-glucose transporter 2 (SGLT2). Steglatro is believed to work by causing excess glucose to be eliminated in the urine.
How do I take it?
Prescribing information states that Steglatro is taken once daily in the morning, with or without food.
Steglatro comes in tablet form.
The FDA-approved label for Steglatro lists yeast infections in women as a common side effect. read more
Rare but serious side effects listed for Steglatro include hypoglycemia (low blood glucose), kidney problems, and urinary tract infections.
For more details about this treatment, visit:
Steglatro.com – Merck
What Are My Options? – American Diabetes Association